Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome

被引:55
作者
Garin, MCB
Kalix, B
Morabia, A
James, RW [1 ]
机构
[1] Univ Hosp, Dept Endocrinol Diabet & Nutr, Clin Diabet Unit, CH-1211 Geneva, Switzerland
[2] Univ Hosp, Dept Clin Epidemiol, CH-1211 Geneva, Switzerland
关键词
D O I
10.1210/jc.2004-1295
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The presence of the metabolic syndrome ( World Health Organization definition) and its association with lipoprotein abnormalities suggestive of greater susceptibility to oxidative stress have been analyzed in patients with angiographically defined coronary artery disease. The odds ratio for the presence of the metabolic syndrome was significantly higher in coronary artery disease-positive patients (P < 0.001). The metabolic syndrome was also associated with more severe coronary disease (P < 0.01). Patients with the metabolic syndrome had significantly decreased low-density lipoprotein-cholesterol/apolipoprotein B and high-density lipoprotein-cholesterol/ apolipoprotein AI ratios, indicative of the presence of small, dense lipoprotein particles. The syndrome was also associated with reduced concentrations and activities of the antioxidant enzyme, paraoxonase-1. The metabolic syndrome is characterized by smaller, denser lipoprotein particles that increase their susceptibility to oxidative modifications and diminished serum paraoxonase-1, which is a major determinant of the antioxidant capacity of high-density lipoproteins. These may be contributory factors to the increased presence and severity of coronary disease in such patients.
引用
收藏
页码:2264 / 2269
页数:6
相关论文
共 36 条
[1]   SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]  
Anwar AJ, 2001, CONTEMP CARDIOL, P3
[3]   Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. [J].
Austin M.A. .
Current Atherosclerosis Reports, 2000, 2 (3) :200-207
[4]  
Avogaro P, 1965, DIABETOLOGIA, V1, P137
[5]  
Balkau B, 1999, DIABETIC MED, V16, P442
[6]   Energy expenditure and substrates oxidative patterns, after glucose, fat or mixed load in normal weight subjects [J].
BobbioniHarsch, E ;
Habicht, F ;
Lehmann, T ;
James, RW ;
RohnerJeanrenaud, F ;
Golay, A .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 1997, 51 (06) :370-374
[7]   Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation [J].
Boemi, M ;
Leviev, I ;
Sirolla, C ;
Pieri, C ;
Marra, M ;
James, RW .
ATHEROSCLEROSIS, 2001, 155 (01) :229-235
[8]   HUMAN HDL CHOLESTEROL LEVELS ARE DETERMINED BY APOA-I FRACTIONAL CATABOLIC RATE, WHICH CORRELATES INVERSELY WITH ESTIMATES OF HDL PARTICLE-SIZE [J].
BRINTON, EA ;
EISENBERG, S ;
BRESLOW, JL .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (05) :707-720
[9]   New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy [J].
Ceriello, A .
DIABETES CARE, 2003, 26 (05) :1589-1596
[10]   The oxidative modification hypothesis of atherogenesis: An overview [J].
Chisolm, GM ;
Steinberg, D .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 28 (12) :1815-1826